Anthony A. Florence Jr.

CIK 1559827 · last filed 2026-03-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$22.46B

Companies

40

Total Filings

108

Lifetime Open-Market Net

$327.02M

Filer Profile

Reported Address
104 5TH AVENUE
19TH FLOOR
NEW YORK, NY 10011
Related Filers
SCOTT D SANDELL — 38 joint filings, latest 2026-08-14
FOREST BASKETT — 37 joint filings, latest 2025-03-12
Peter W. Sonsini — 31 joint filings, latest 2022-08-05
NEA 14 GP, LTD — 24 joint filings, latest 2026-08-14
NEA Partners 14, L.P. — 24 joint filings, latest 2026-08-14
New Enterprise Associates 14, L.P. — 23 joint filings, latest 2026-08-14
PATRICK J KERINS — 20 joint filings, latest 2024-05-15
Mohamad Makhzoumi — 16 joint filings, latest 2026-08-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KRRO 10%+ Owner 1,297,893 $13.81 $17.92M $3.30M 2 2026-03-12
SGP 10%+ Owner 2,989,408 $27.52 $82.27M $15.00M 1 2026-02-11
NeueHealth, Inc. (BHG) Delisted Director 0 $16.35 $0 $34.97M 8 2025-10-06
NeueHealth, Inc. (NEUE) Delisted 10%+ Owner $6.75 $0 2 2024-10-03
MBX 10%+ Owner 1,023,103 $59.02 $60.38M $8.00M 1 2024-09-17
SVRA 10%+ Owner 24,471,264 $5.30 $129.70M $1000.0K 1 2023-07-19
MIRM 10%+ Owner 384 $98.22 $37.7K $6.75M 2 2023-06-15
Arcellx, Inc. (ACLX) Delisted 10%+ Owner 0 $115.07 $0 $5.5K 1 2022-12-22
Akouos, Inc. (AKUS) Delisted 10%+ Owner 0 $13.29 $0 $10.00M 2 2022-12-02
IONQ.WS 10%+ Owner 0 $25.41 $0 $0 1 2022-11-18
AVEO PHARMACEUTICALS, INC. (AVEO) Delisted 10%+ Owner 0 $15.00 $0 $24.62M 17 2022-10-21
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted 10%+ Owner 0 $0.00 $0 $21.03M 4 2022-05-26
HOOD Director 326,913 $112.57 $36.80M -$49.2K 5 2022-05-04
TRVI 10%+ Owner 10,421,428 $15.90 $165.70M $31.80M 4 2022-04-13
Casper Sleep Inc. (CSPR) Delisted Director 0 $6.78 $0 $15.00M 4 2022-01-26
Enliven Therapeutics, Inc. (IMRA) Delisted 10%+ Owner 864,966 $14.59 $12.62M -$2.52M 2 2022-01-20
Metacrine, Inc. (MTCR) Delisted 10%+ Owner 2,563,257 $0.49 $1.27M $9.51M 2 2021-12-27
GLUE 10%+ Owner 5,973,296 $14.07 $84.04M $19.95M 1 2021-06-30
Desktop Metal, Inc. (DM) Delisted 10%+ Owner 81 $4.96 $402 $0 1 2021-06-10
Eargo, Inc. (EAR) Delisted 10%+ Owner 1,500 $2.57 $3.9K $5.60M 2 2021-05-26
MRKR 10%+ Owner 1,071,428 $1.15 $1.23M $10.00M 1 2021-03-18
Regulus Therapeutics Inc. (RGLS) Delisted 10%+ Owner 645,106 $8.16 $5.26M $3.96M 3 2020-12-07
Mersana Therapeutics, Inc. (MRSN) Delisted 10%+ Owner 928 $29.08 $27.0K $14.82M 3 2020-09-16
Inozyme Pharma, Inc. (INZY) Delisted 10%+ Owner 2,000,533 $4.00 $8.00M $4.00M 1 2020-07-28
NKTX 10%+ Owner 522,639 $2.91 $1.52M $12.00M 1 2020-07-16
Adaptimmune Therapeutics PLC (ADAP) Delisted 10%+ Owner 19,500,000 $0.06 $1.13M $5.00M 1 2020-01-28
ARDX 10%+ Owner 3,082,186 $3.58 $11.03M $23.33M 4 2019-12-09
Galera Therapeutics, Inc. (GRTX) Delisted 10%+ Owner 19,707 $17.60 $346.8K $50.00M 1 2019-11-12
ASND 10%+ Owner 82,978,668 $263.51 $21.87B $49.02M 4 2018-09-10
Surface Oncology, Inc. (SURF) Delisted 10%+ Owner 3,312,877 $1.07 $3.54M $2.00M 1 2018-04-23
Oruka Therapeutics, Inc. (ABIO) Delisted 10%+ Owner 0 $28.80 $0 -$731.3K 1 2018-02-27
Cascadian Therapeutics, Inc. (CASC) Delisted 10%+ Owner 10,882,574 $0 1 2018-02-22
APPN 10%+ Owner 1,245 $34.76 $43.3K -$66.07M 4 2018-02-15
SYNLOGIC, INC. (SYBX) Delisted 10%+ Owner 281,929 $0.69 $194.5K $0 2 2018-01-26
MULESOFT, INC (MULE) Delisted 10%+ Owner 0 $0 1 2017-03-22
Achaogen, Inc. (AKAO) Delisted 10%+ Owner 5,215,128 $6.75M 1 2016-12-19
Avalo Therapeutics, Inc. (CERC.U) Delisted 10%+ Owner 594,245 $0 1 2015-10-20
SYNLOGIC, INC. (MIRN) Delisted 10%+ Owner 1,241,650 $6.00M 1 2015-10-06
CVENT INC (CVT) Delisted Director 441 $8.52 $3.8K -$23.0K 6 2015-06-11
Loxo Oncology, Inc. (LOXO) Delisted 10%+ Owner 1,789,420 $3.00M 1 2014-08-06

Recent Filings · Page 5 of 11

108 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-09-16 Mersana Therapeutics, Inc. (MRSN) Delisted Other (J) −1,988,665 $0 EDGAR
2020-07-28 Inozyme Pharma, Inc. (INZY) Delisted Mixed +2,437,689 $4.00M EDGAR
2020-07-28 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Buy (P) +3,151,260 $7.09M EDGAR
2020-07-16 NKTX Mixed +2,902,115 $12.00M EDGAR
2020-07-01 Akouos, Inc. (AKUS) Delisted Mixed +4,294,207 $10.00M EDGAR
2020-06-22 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +1,428,571 $7.50M EDGAR
2020-04-13 TRVI Mixed +1,499,436 -$0 EDGAR
2020-04-13 Mersana Therapeutics, Inc. (MRSN) Delisted Mixed −3,997,865 -$177.8K EDGAR
2020-03-09 Casper Sleep Inc. (CSPR) Delisted Grant (A) +17,332 $0 EDGAR
2020-02-12 Casper Sleep Inc. (CSPR) Delisted Buy (P) +1,250,000 $15.00M EDGAR
Showing 4150 of 108
Page 5 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.